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Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable burden
from disease activity and damage. A novel clinical treatment target in the form of the lupus low disease activity
state (LLDAS) has been recently reported, with retrospective validation showing that time spent in LLDAS translates
to reduced damage accrual. The objectives of this study were to describe the frequency and identify the predictors
of attaining LLDAS in a large multinational cohort of patients with SLE.
Methods: Data were collected at the recruitment visit in patients with SLE enrolled in a longitudinal study in nine
countries. Data were analysed cross-sectionally against the recently published definition of LLDAS, and the
frequency and characteristics associated with presence of LLDAS were determined. Stepwise multivariable
logistic regression was used to determine predictors of LLDAS.
Results: Of the 1846 patients assessed, criteria for LLDAS were met by 44 %. Patients with shorter disease
duration were less likely to be in LLDAS (OR 0.31, 95 % CI 0.19–0.49, p < 0.001). Likewise, patients with a history of discoid
rash (OR 0.66, 95 % CI 0.49–0.89, p = 0.006), renal disease (OR 0.60, 95 % CI 0.48–0.75, p< 0.001), elevated double stranded
DNA (OR 0.65, 95 % CI 0.53–0.81, p < 0.001) or hypocomplementaemia (OR 0.52, 95 % CI 0.40–0.67, p < 0.001) were less
likely to be in LLDAS. When countries were compared, higher national social wealth (OR 1.57, 95 % CI 1.25–1.98, p < 0.001)
as measured by the gross domestic product per capita was positively associated with LLDAS, but ethnicity was not.
Conclusion: The lupus low disease activity state is observed in less than half of patients with SLE at a single point in time.
Disease duration and phenotype, and national social wealth, are predictive of LLDAS.
Keywords: Systemic lupus erythematosus, Disease activity, Treatment target, Low disease activity
Background
Systemic lupus erythematosus (SLE) is a chronic multi-
organ autoimmune disease with a broad spectrum of
manifestations. Despite global advances in translational
research, effective targeted therapies in SLE are lacking
[1], and a large proportion of patients are treated with
long-term glucocorticoids and non-specific immunosup-
pressants, which fail to prevent significant morbidity and
reduction in life expectancy [2]. The course of SLE is
variable, in some cases characterized by periods of rela-
tive inactivity punctuated by disease flare, whilst others
have persistently active disease [3]. Current instruments
used to measure disease activity are complex [4], con-
tributing to mixed results in clinical trials of new tar-
geted therapies [5]. This state of affairs has lead to a call
for definitions of treatment target states that can be used
in clinical trials and clinical practice [6].
* Correspondence: vera.golder@monash.edu; vera.golder@gmail.com
†Equal contributors
1Monash University, Melbourne, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Golder et al. Arthritis Research & Therapy  (2016) 18:260 
DOI 10.1186/s13075-016-1163-2
Given that definitions of remission remain under de-
bate [7], and a recently reported stringent definition of
remission occurs in only 2 % of patients with SLE [8],
using remission as a treatment target is not pragmatic.
In other autoimmune diseases, mainly rheumatoid
arthritis (RA), achieving a minimally active disease
state has been proven to translate into improved pa-
tient outcomes [9]. The value of a treatment target
for SLE has been recently described in an inter-
national consensus statement, in which defining a low
disease activity state to use as a treatment target was
set as a research agenda [10].
Using consensus methods, the Asia-Pacific Lupus
Collaboration has recently developed and retrospectively
validated the lupus low disease activity state (LLDAS)
definition [11]. The conceptual definition of LLDAS is a
state, which if sustained, is associated with good long-
term outcomes. The operational definition of LLDAS is
fulfilled when all of the following criteria are met: (1)
SLE Disease Activity Index (SLEDAI-2 K) ≤4, with no
activity in major organ systems (renal, central nervous
system (CNS), cardiopulmonary, vasculitis, fever) and no
haemolytic anaemia or gastrointestinal activity; (2) no
new features of lupus disease activity compared to the
previous assessment; (3) a Safety of Estrogens in Lupus
Erythematosus National Assessment (SELENA)-SLEDAI
physician global assessment (PGA) (scale 0–3) ≤1; (4) a
current prednisolone (or equivalent) dose ≤7.5 mg daily;
and (5) well-tolerated standard maintenance doses of
immunosuppressive drugs and approved biologic agents,
excluding investigational drugs. In a retrospective cohort
analysis, Franklyn et al. showed that patients who spent
greater than 50 % of their disease duration in LLDAS
accrued significantly less damage compared to patients
who did not [11], suggesting this definition has a role in
the identification of treatment responses associated with
improved long-term outcomes.
Currently, work is underway to prospectively validate
and refine this definition of LLDAS in a large multi-
national cohort followed over several years, with the
hypothesis that attainment of LLDAS results in less
damage accrual. The objective of the current study is to
determine the frequency and correlates of LLDAS in a
cross-sectional analysis of data collected at recruitment
for this study.
Methods
Study population
Patients were recruited at 12 centres in nine countries,
commencing in May 2013. Each institution obtained
ethics approval and written informed patient consent for
the study. Patients over the age of 18 years who fulfilled
criteria for SLE (either the 1997 American College of
Rheumatology (ACR) criteria [12] or the 2012 Systemic
Lupus International Collaborating Clinics (SLICC)
criteria [13]) were eligible. Data collection took place
during the routine ambulatory care of each SLE patient,
using a standardized paper or electronic case report
form.
Variables
At recruitment, demographics, disease characteristics
and clinical variables were collected from each patient.
Demographic variables included gender, ethnicity (self-
report based on Australian Standard Classification of
Cultural and Ethnic Groups [14]), date of birth, year of
definite SLE diagnosis, smoking status, and highest
attained education level. Disease manifestations were
determined from the ACR classification criteria on an
“ever present” basis. Current use and doses of glucocor-
ticoids and immunosuppressive medications were cap-
tured for each patient. Disease activity was measured
using SLEDAI-2 K [15], and a PGA on a scale of 0–3.
Disease flares compared to the previous routine clinical
visit were captured using the SLE flare index (SFI) [16].
Irreversible disease damage was captured using the
SLICC damage index (SLICC-DI) [17]. Additionally,
laboratory results for each patient were obtained within
30 days of the visit, including full blood count, renal
function and electrolytes, serum albumin, urine protein/
creatinine ratio and microscopy, erythrocyte sedimenta-
tion rate, complement 3 and 4, and double stranded
DNA (dsDNA) antibody titre.
Determination of LLDAS
A patient was considered to be in LLDAS if they fulfilled
all five predefined criteria [11], with the following modi-
fications. Given the cross-sectional nature of the baseline
visit, data collected at recruitment, and hence the ab-
sence of data from the previous visit, patients were
deemed to be on stable doses of immunosuppressive
medications if they did not exceed the maximum recom-
mended dose (Table 3); the criterion for “no new disease
activity” was deemed to be met if patients did not meet
any SFI criteria.
Data analysis
Given the young mean age of the patients (Table 1), age
at diagnosis ≤30 years was used as a binary variable.
Given the likelihood of higher disease activity in the
period immediately after diagnosis of SLE [18], disease
duration ≤1 year was also used as a binary variable.
Patients from different countries were grouped accord-
ing to gross domestic product (GDP) purchasing power
parity per capita [19] in order to account for inter-
national differences in socioeconomic status.
Pooled data from all sites were analysed using STATA
v13 (StataCorp, College Station, TX, USA). Data are
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reported as mean (standard deviation (SD)) for normally
distributed continuous variables and median (interquar-
tile range (IQR)) for skewed continuous data. The chi-
squared test was used for categorical comparisons.
Univariate simple logistic regression was used to identify
predictors of LLDAS. Variables with p value ≤0.2 in sim-
ple logistic regression analysis were then checked for
confounding and multicollinearity, prior to inclusion in
stepwise multivariable logistic regression analysis for
LLDAS. Model properties including sensitivity and
specificity, receiver operating characteristic (ROC) and p
value for the Hosmer-Lemeshaw test for goodness of fit
are available in Additional file 1: Table S1.
Results
Demographics and disease characteristics
A total of 1846 patients were recruited. In this cohort,
93 % of patients were female, with a mean age at diagno-
sis of 29 (SD ± 12.4) years and mean disease duration of
8.6 (SD ± 8.5) years at the time of recruitment. There
were 149 patients (8 %) recruited within 12 months of
disease diagnosis. More than 50 % of patients were of
Chinese ethnicity, 7 % of patients were Caucasian, and
the remainder represented other ethnic groups native to
the region (Table 1). Other baseline demographics are
presented in Table 1.
Disease manifestations were determined from the
ACR criteria on an “ever present” basis (Table 1).
More than half of the patients had a history of malar
rash, arthritis and haematologic and immunologic
Table 1 Patient demographics and disease characteristics
Number (%)c or mean (SD)
or median (IQR 25–75)
(n = 1846 patients)
Country
Australia 240 (13.00 %)
China 235 (12.73 %)
Hong Kong 190 (10.29 %)
Indonesia 98 (5.31 %)
Malaysia 193 (10.46 %)
Philippines 124 (6.72 %)
Singapore 221 (11.97 %)
Taiwan 295 (15.98 %)
Thailand 250 (13.54 %)
Ethnicity
Caucasian 126 (6.73 %)
Chinese 1008 (54.60 %)
Filipino 132 (7.15 %)
Indonesian 102 (5.53 %)
Thai 255 (13.81 %)
Malay 98 (5.31 %)
Vietnamese/Cambodian 24 (1.30 %)
Indian/Sri Lankan 64 (3.47 %)
Othera 37 (2.00 %)
Female gender 1723 (93.34 %)
Age at diagnosis (years) 29.34 (12.35)
Age at diagnosis ≤30 years 973 (52.71 %)
Disease duration at enrollment (years) 8.64 (8.50)
Disease duration at enrollment ≤1 year 149 (8.07 %)
Current smoker 67 (3.63 %)
First-degree relative with SLE 117 (6.34 %)
Highest attained education level
Primary 242 (13.11 %)
Secondary 572 (30.99 %)
Tertiary 618 (33.48 %)
ACR criteriab
Malar rash 1087 (58.88 %)
Discoid rash 290 (15.71 %)
Photosensitivity 537 (29.09 %)
Mouth ulcers 670 (36.29 %)
Arthritis 1205 (65.28 %)
Serositis 313 (16.96 %)
Renal 803 (43.50 %)
Neurologic 160 (8.67 %)
Haematologic 1118 (60.56 %)
Immunologic 1547 (83.80 %)
Table 1 Patient demographics and disease characteristics
(Continued)
ANA 1627 (88.14 %)
Number of ACR criteria for SLE 5.07 (1.39)
Number of SLICC criteria for SLE 5.70 (2.47)
SLICC-DI score at enrollment 0 (0–1)
Damage present at enrollmentd 694 (37.59 %)
PGA at enrollment 0.6 (0.3–1)
Mild flare since last clinical review 210 (11.38 %)
Severe flare since last clinical review 111 (5.94 %)
SLEDAI-2 K score 4 (2–6)
SLEDAI-2 K no complement or dsDNA 0 (0–4)
aOther includes Hispanic, African, other South-East Asian, Pacific Islander and
mixed ethnicity. bEver present arthritis (two or more joints with tenderness,
swelling or effusion), serositis (pleuritis or pericarditis), renal disorder (persistent
proteinuria >0.5 g/day, or presence of cellular casts), neurologic disorder
(seizures or psychosis not attributable to other causes), haematologic
disorder (haemolytic anaemia, leukopenia, lymphopenia or thrombocytopenia),
immunologic criteria (presence of anti-dsDNA antibody, anti-Sm antibody, or
positive finding of antiphospholipid antibodies). cPercent present shown in table,
percent absent and missing not shown in table. dSLICC-DI >0. SLE systemic lupus
erythematosus, ACR American College of Rheumatology, SLEDAI SLE
disease activity index, SLICC Systemic Lupus International Collaborating Clinics,
DI damage index, PGA Physician Global Assessment, ANA antinuclear antibody,
dsDNA double-stranded DNA
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manifestations, and 803 patients (44 %) had a history
of renal disease. The median SLEDAI-2 K at enroll-
ment was 4 (IQR 2–6) (Table 1). There were 694
patients (38 %) had irreversible damage at recruit-
ment (SLICC-DI >0), and the median SLICC-DI score
was 0 (IQR 0–1). In total, 1430 patients (77.5 %)
were on prednisolone, with a mean dose of 11 mg
(SD ± 12.8 mg) per day (Table 2).
Frequency of meeting criteria for LLDAS
All of the patients fulfilled at least one criterion of
LLDAS (Table 3). The most frequently present criterion
(n = 1838 patients (99.6 %)) was the criterion relating to
immunosuppressive medications, with only eight pa-
tients exceeding a maximum recommended dose. The
least frequently present criterion (1171 patients (63.4 %))
was SLEDAI-2 K ≤4 without activity in a major organ
system, followed by the glucocorticoid dose criterion
(68.2 %). A higher proportion of patients achieved PGA
≤1 than achieved SLEDAI ≤4 (76 % vs. 63 %, p < 0.001).
Despite a high frequency of attainment of individual
criteria, only 810 patients (43.9 %) fulfilled all five
criteria for LLDAS.
Determinants of presence of LLDAS
Multiple independent variables had a significant asso-
ciation with LLDAS in univariate analysis (Table 4).
Younger age at diagnosis (OR 0.77, 95 % CI 0.64–
0.93, p = 0.006) and shorter disease duration (OR 0.34,
95 % CI 0.23–0.51, p < 0.001) were negatively associ-
ated with LLDAS. A history of discoid rash (OR 0.73,
95 % CI 0.57–0.95, p = 0.02) or renal disease (OR
0.63, 95 % CI 0.53–0.77, p < 0.001), or current anti-
dsDNA positivity (OR 0.55, 95 % CI 0.46–0.68, p <
0.001) and hypocomplementaemia (low C3 and or C4;
OR 0.45, 95 % CI 0.37–0.55, p < 0.001) were all negatively
associated with LLDAS. No significant differences were
observed in ethnicity, gender or educational level. In mul-
tivariable logistic regression analysis, variables that
remained significantly negatively associated with LLDAS
included disease duration ≤1 year (OR 0.31, 95 % CI 0.19–
0.49, p < 0.001), history of discoid rash (OR 0.66, 95 % CI
0.49–0.89, p = 0.006) or renal disease (OR 0.60, 95 % CI
0.48–0.75, p < 0.001); and current elevated anti-dsDNA
(OR 0.65, 95 % CI 0.53–0.81, p < 0.001) or hypocomple-
mentaemia (OR 0.52, 95 % CI 0.40 − 0.67, p < 0.001).
Patients from countries with a high GDP (PPP) per capita
were significantly more likely to be in LLDAS than pa-
tients from countries with a lower GDP (PPP) per capita
(OR 1.57, 95 % CI 1.25–1.98, p < 0.001). Model properties
for the aforementioned variables are presented in
Additional file 1: Table S1.
Analysis of the effect of disease manifestations as
defined by ACR criteria [12] on individual LLDAS
criteria (Additional file 1: Table S2) revealed that
patients with immunologic manifestations were less
likely to have SLEDAI-2 K ≤4 (OR 0.73, 95 % CI
0.56–0.96, p = 0.02). A history of renal disease was
significantly associated with lower odds of meeting
any of the individual LLDAS criteria. The presence of
damage (SLICC-DI >0) at recruitment was signifi-
cantly associated with lower frequency of meeting
several LLDAS criteria including SLEDAI ≤4 (OR
0.79, 95 % CI 0.65–0.96, p = 0.02), absence of flare
(OR 0.67, 95 % CI 0.52–0.88, p = 0.003) and PGA ≤1
(OR 0.64, 95 % CI 0.51–0.79, p < 0.001).
Table 2 Medication taken at enrollment
Medication Number (%) Mean dose (SD) Dose range
Prednisolone 1430 (77.46 %) 11.08 mg (12.78) 0.50–200 mg
Antimalarial 1333 (72.21 %) 291.19 mg (104.56)a 28.57–600 mga
Methotrexate 75 (4.06 %) 13.79 mg (6.73) 2.50–50 mg
Azathioprine 412 (22.32 %) 73.99 mg (30.29) 12.50–200 mg
Mycophenolate mofetil 306 (16.58 %) 1247.70 mg (546.96) 50–3000 mg
Mycophenolic acid 41 (2.22 %) 1102.93 mg (645.86) 180–2160 mg
Leflunomide 38 (2.06 %) 15.53 mg (5.49) 10–30 mg
Cyclosporine 35 (1.90 %) 126.43 mg (65.29) 50–300 mg
Cyclophosphomideb 73 (3.95 %) N/A N/A
Rituximabb 13 (0.70 %) N/A N/A
Belimumabb 15 (0.81 %) N/A N/A
Any Immunosuppressantc 940 (50.92 %) N/A N/A
aBased on hydroxychloroquine dosing - Indonesia and Thailand predominantly use chloroquine. bTaken in the last 6 months. cEither methotrexate, azathioprine,
mycophenolate, leflunomide, cyclosporine, cyclophosphamide, rituximab and/or belimumab. Maximum recommended dose: hydroxychloroquine ≤400 mg;
methotrexate ≤30 mg; azathioprine ≤200 mg; mycophenolate mofetil ≤3000 mg; mycophenolic acid ≤2160 mg; leflunomide ≤20 mg
N/A - dosing not applicable
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Discussion
The authors have commenced a large prospective lon-
gitudinal study to validate the recently reported defin-
ition of LLDAS as being predictive of protection from
damage accrual in SLE [11]. In the current cross-
sectional study of data collected at recruitment into
this large multinational cohort, we have shown that
44 % of patients with SLE met LLDAS criteria for
low disease activity at a single point in time. This is
the first multinational study to focus on the recent
definition of LLDAS, and the frequency of LLDAS
observed closely matches the 41 % frequency of
LLDAS attainment in our initial retrospective single-
centre validation study [11]. If LLDAS attainment or
maintenance is shown to translate into improved pa-
tient outcomes, such as is the case for attainment of
minimal disease activity in RA [9], this frequency of
attainment, especially compared to more stringent
cutoffs such as remission, suggests that LLDAS could
represent a treatment target to use in SLE strategy
trials and in clinical trials of novel therapies. Con-
versely, the fact that the majority of patients did not
meet criteria for LLDAS speaks to the inadequate
state of current treatment of SLE.
The definition of LLDAS [11] incorporates cutoffs for
both disease activity and treatment burden. It refers to a
desired clinical state, rather than a treatment response
or change in disease activity, therefore representing a
tool with which to stratify clinically diverse disease man-
ifestations in a binary fashion, i.e. a patient is either in
LLDAS or not. LLDAS was designed to take into ac-
count validated measures of disease activity [20] and
treatment variables, in view of the fact that treatment,
especially with glucocorticoids, is known to contribute
to poor long-term outcomes in SLE [21, 22]. In the
current study, the second most frequent reason for not
attaining LLDAS was glucocorticoid dose >7.5 mg/day.
Although it is clear that higher disease activity over time
is associated with worse outcomes [23], measures of
disease activity alone, such as the SLEDAI-2 K or the
British Isle Lupus Assessment Group (BILAG) measure,
do not take into account treatment burden and therefore
omit consideration of a major contributor to long-term
harm in SLE. Similarly, measures of treatment response
such as the SLE Responder Index [24], although they
combine different measures of disease activity, do not
represent a target state and do not include treatment
variables.
Our finding that 99 % of patients met at least one
LLDAS criterion, but only 44 % of patients met all five
criteria, supports the value of including multiple vari-
ables in the definition of LLDAS. A higher proportion of
patients achieved PGA ≤1 than achieved SLEDAI ≤4,
potentially because of the inclusion of serological and
clinical activity in the SLEDAI-2 K; the presence of
dsDNA antibodies and hypocomplementaemia equates
to 4 points on the SLEDAI-2 K, therefore any additional
manifestation will result in the patient exceeding the
SLEDAI-2 K cutoff for LLDAS.
The size of this cohort allowed us to evaluate factors
associated with the presence of LLDAS. Some of the
most common clinical manifestations of active disease
in SLE are immunologic, cutaneous and renal disease
[3], each of which was significantly negatively associ-
ated with LLDAS in multivariable regression. Disease
duration of less than one year was also negatively as-
sociated with LLDAS, consistent with the observation
that newly diagnosed patients are more likely to have
active disease [18].
Our study has shed some further light on treatment
practices in tertiary lupus centres. The lower frequency
of use of immunosuppressants in this cohort may be
related to issues with access to or availability of medi-
cations in some Asian countries, which has been pre-
viously described [26]; certainly in our recent single
centre report based on an Australian cohort, the fre-
quency of immunosuppressant use was considerably
higher than in the present study [11]. The mean daily
dose of prednisolone of 11 mg/day is higher than
doses reported in recent studies in single-centre
cohorts with similar mean disease duration [11, 22].
As prolonged prednisolone use is known to contrib-
ute to significant morbidity in SLE [27], the conse-
quences of high glucocorticoid dosing in this cohort
Table 3 Lupus low disease activity state (LLDAS) frequency
Descriptors of disease activity Number (%)
(n = 1846)
1. SLEDAI-2 K ≤4, with no activity in major
organ systems (renal, CNS, cardiopulmonary,
vasculitis, haemolytic anaemia, fever) and no
gastrointestinal activity
1171 (63.43 %)
2. No new features of lupus disease activity
compared to the previous assessment
1574a (85.27 %)
3. SELENA-SLEDAI Physician Global Assessment
(PGA, scale 0–3) ≤1
1400 (75.84 %)
Immunosuppressive medications
4. Current prednisolone (or equivalent)
dose ≤7.5 mg daily
1258 (68.15 %)
5. Well-tolerated standard maintenance doses
of immunosuppressive drugs and approved
biologic agents, excluding investigational drugsb
1838 (99.57 %)
All 5 criteria present 810 (43.88 %)
aBased on flares (see “Methods”). bCalculated as not exceeding maximum
recommended dose: hydroxychloroquine ≤400 mg; methotrexate ≤30 mg;
azathioprine ≤200 mg; mycophenolate mofetil ≤3000 mg; mycophenolic acid
≤2160 mg; leflunomide ≤20 mg. SLE systemic lupus erythematosus, SELENA
Safety of Estrogens in Lupus Erythematosus National Assessment trial, SLEDAI
SLE disease activity index, CNS central nervous system, PGA Physician
Global Assessment
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Table 4 Determinants of lupus low disease activity state (LLDAS)
Independent variable Number (%) in LLDAS Univariable logistic regression for LLDAS Multivariable logistic regression for LLDAS
OR (95 % CI) p OR (95 % CI) p
Ethnicitya
Caucasian 63 (50.00) Reference Reference
Asian 700 (43.24) 0.76 (0.53–1.09) 0.14 1.23 (0.82–1.86) 0.31
Gender
Female 758 (43.99) Reference N/A
Male 52 (42.28) 0.93 (0.64–1.35) 0.71
Education
Primary 113 (46.69) Reference N/A
Secondary 229 (40.03) 0.76 (0.56–1.03) 0.21
Tertiary 254 (41.10) 0.80 (0.59–1.07) 0.30
Age at diagnosis
>30 years 407 (47.22) Reference Reference
≤30 years 397 (40.80) 0.77 (0.64–0.93) 0.006 0.86 (0.70–1.06) 0.16
Disease duration
>1 year 765 (46.48) Reference Reference
≤1 year 34 (22.82) 0.34 (0.23–0.51) <0.001 0.31 (0.19–0.49) <0.001
Clinical featuresb
Malar rash
No 331 (43.61) Reference N/A
Yes 479 (44.07) 1.02 (0.82–1.23) 0.85
Discoid rash
No 701 (45.05) Reference Reference
Yes 109 (37.59) 0.73 (0.57–0.95) 0.02 0.66 (0.49–0.89) 0.006
Photosensitive
No 562 (42.93) Reference Reference
Yes 248 (46.18) 1.14 (0.93–1.40) 0.20 1.18 (0.93–1.50) 0.16
Mouth Ulcers
No 527 (44.81) Reference N/A
Yes 283 (42.24) 0.90 (0.74–1.09) 0.28
Arthritis
No 263 (41.03) Reference Reference
Yes 547 (45.39) 1.19 (0.98–1.45) 0.07 0.98 (0.78–1.23) 0.87
Serositis
No 673 (43.90) Reference N/A
Yes 137 (43.77) 0.99 (0.78–1.27) 0.97
Renal
No 508 (48.71) Reference Reference
Yes 302 (37.61) 0.63 (0.53–0.77) <0.001 0.60 (0.48–0.75) <0.001
Neurologic
No 732 (43.42) Reference Reference
Yes 78 (48.75) 1.24 (0.90–1.72) 0.20 1.31 (0.90–1.91) 0.16
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with mean disease duration at recruitment close to
9 years will need to be further assessed.
It is well-established that personal socioeconomic sta-
tus contributes to disease activity [28] and disease dam-
age [29] in SLE. A recent study from the Asia Pacific
region has also shown that national social wealth and
development has a very strong association with 5-year
survival among patients with SLE [25]. As such, we be-
lieved it important to include an index of socioeconomic
wealth in analyzing predictors of LLDAS. Indeed, in our
study, patients from countries with higher GDP per
capita (PPP) were significantly more likely to meet all
criteria for LLDAS. The GDP (PPP) per capita is ad-
justed for the cost of living and is therefore useful for
comparing standards of living rather than just national
wealth [19]. The main drawback of this measure is that
it does not measure personal socioeconomic status,
which would also vary from patient to patient. However,
education level, a potential surrogate marker of individ-
ual socioeconomic standing, was not predictive of
LLDAS.
Certain limitations apply to the current study. Be-
cause of the cross sectional nature of the current
analysis, we are unable to ascertain whether time
spent in LLDAS is associated with less damage ac-
crual, as was shown in the original retrospective
single-centre validation of LLDAS [11]. The cohort
described here is the subject of a longitudinal study
intended to determine the association of LLDAS
attainment with outcomes including damage accrual.
Additionally, the published definition of LLDAS
requires the absence of new disease manifestations,
which is not possible to measure in a cross-sectional
study; we replaced this with a requirement for the
absence of flare as measured using SFI, which is
likely to have been more rather than less stringent.
In addition, identification of the “well-tolerated
immunosuppressive” component of LLDAS was
modified due to the inability to determine dose
change or tolerance at recruitment. This resulted in
a high proportion of patients fulfilling this criterion,
and use of the original definition in our longitudinal
Table 4 Determinants of lupus low disease activity state (LLDAS) (Continued)
Haematologic
No 289 (39.70) Reference Reference
Yes 521 (46.60) 0.22 (0.03–1.76) 0.09 1.21 (0.97–1.51) 0.09
Immunologic
No 145 (48.59) Reference N/A
Yes 665 (42.99) 0.80 (0.63–1.03) 0.08
ANA
No 101 (46.12) Reference N/A
Yes 709 (43.58) 0.90 (0.68 − 1.20) 0.48
Baseline damage
SLICC-DI = 0 505 (44.84) Reference N/A
SLICC-DI >0 308 (42.95) 1.00 (0.83–1.21) 0.96
Current high anti-dsDNA
No 434 (51.12) Reference Reference
Yes 341 (36.43) 0.55 (0.46–0.68) <0.001 0.65 (0.53–0.81) <0.001
Current low complement
No 636 (49.88) Reference Reference
Yes 142 (29.83) 0.45 (0.37–0.55) <0.001 0.52 (0.40–0.67) <0.001
GDP≤ $25,000c 324 (36.00) Reference Reference
GDP > $25,000 486 (51.37) 1.89 (1.56–2.26) <0.001 1.57 (1.25–1.98) <0.001
Multivariable model choice - variables with a p value ≤0.20 or clinical association in univariable regression were tested for multicolliniarity and confounding.
Final variable list - GDP (PPP) per capita, ethnicity, age at diagnosis, disease duration, discoid rash, photosensitivity, arthritis, renal disease, neurologic disease,
haematologic disease, dsDNA and complement. aEthnicity – no significant differences were seen between Asian ethnicity subgroups. bEver present, arthritis (two
or more joints with tenderness, swelling or effusion), serositis (pleuritis or pericarditis), renal disorder (persistent proteinuria >0.5 g/day, or presence of cellular
casts), neurologic disorder (seizures or psychosis not attributable to other causes), haematologic disorder (haemolytic anaemia, leukopenia, lymphopenia or
thrombocytopenia), immunologic criteria (presence of anti-dsDNA antibody, anti-Sm antibody, or positive finding of antiphospholipid antibodies). cCountries with
GPD < $25,000 - China, Indonesia, Malaysia, Philippines, Thailand; countries with GDP > $25,000 - Australia, Hong Kong, Singapore, Taiwan. GDP measured in US
dollars. N/A variable not included in multivariable regression model
LLDAS lupus low disease activity state, SLICC Systemic Lupus International Collaborating Clinics, DI damage index, dsDNA double-stranded DNA, ANA antinuclear
antibody, GDP gross domestic product
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study may result in a lower overall frequency of
LLDAS.
Conclusions
In conclusion, a validated definition of low disease activ-
ity has transformed both clinical care and clinical trial
design in RA. Defining a treatment outcome that is
attainable in an achievable proportion of patients and as-
sociated with improved long-term outcomes is some-
thing that has eluded SLE researchers until recently.
Here, we have shown in a large multi-national and
multi-ethnic cohort that LLDAS is attainable in a signifi-
cant proportion of patients analysed at a single point in
time, suggesting this definition is practical for use in
long-term studies. We have also identified clinical vari-
ables associated with reduced likelihood of LLDAS,
which if confirmed in longitudinal studies, may help
with early identification of patients at higher risk. The
next step in validation of LLDAS as an outcome meas-
ure in SLE is the definitive evaluation of whether LLDAS
attainment or maintenance is associated with protection
from long-term adverse outcomes such as damage
accrual. This validation study, which will also allow for
potential refinement of the LLDAS definition based on
identifying variables that are most predictive of good
outcomes, as was done for the recently described re-
definition of remission in RA [30], is underway. That
less than half of patients studied met the definition of
LLDAS serves to underline the need for advances in the
care of SLE, for which new strategies and new drugs are
needed.
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